Seattle Genetics CEO Clay Siegall may be the man who ushers in the drug we’ve all been waiting for, the elusive and long-awaited cure for cancer. He spent his entire adult life pursuing that goal. He earned an undergraduate degree in Zoology from the University of Maryland, followed by a Ph. D. in genetics from George Washington University. He spent several years working for Bristol-Myers Squibb Pharmaceutical Research Institute before going to work for the National Cancer Institute and National Institutes of Health. In 1998, he co-founded Seattle Genetics.
Seattle Genetics is best known for its cancer drug ADCETRIS, which, simply put, allows doctors to target cancer cells directly, leaving healthy cells alone. This is a significant step in cancer treatment because it reduces the horrible side effects of traditional cancer treatments. In the coming months and years, Seattle Genetics expects the FDA to approve ADCETRIS for labeling and use against an expanded number of cancer types.
The success of Seattle Genetics is not all Clay Siegall has going for him. In 2013 he was appointed to the Mirna Therapeutics Board of Directors. Mirna Therapeutics works with micro RNA (miRNA), which are sequences of nucleotides that interact with messenger RNA to regulate gene expression. Mirna Therapeutics has discovered that disregulated miRNA play a role in cancer formation, and that replacing down regulated miRNA with health miRNA has a positive effect on cancerous tumors. Mirna Therapeutics has a host of pharmaceuticals with high potential waiting to be presented to and approved by the FDA, and Clay Siegall is going to be right there lending his knowledge and experience to the process.
There are few men today who have been at the forefront of cancer research the way Seattle Genetics CEO Clay Siegall has been. By lending his leadership and experience in so many places where it is needed, Mr. Siegall could very well be the man who finally brings the world a cure for cancer.